Sol-gel Technologies Ltd. · NASDAQ:SLGL
Sol-gel Technologies — Investor Presentation (January 2022)
17 slides from Sol-gel Technologies's investor presentation, Jan 5, 2022
Slide 1: Sol-Gel: Advanced Topical Therapy
$ Sol- Gel ey nced Topical Therapy
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,
Slide 3: Pioneering Topical Drugs in Acne and Rosacea
EPSOLAY®Benzoyl Peroxide Cream, 5%forInflammatory Lesions of Rosacea PIONEERING TOPICAL DRUGS IN ACNE AND ROSACEA Potential to Change Treatment Landscape* * EPSOLAY is investigational drug product. Safety and efficacy have not been established TWYNEO® Tretinoin and Benzoyl Peroxide Cream, 0.1%/3%for
Slide 4: Partnering with Market Leader Galderma
PARTNERING WITH MARKET LEADER GALDERMA Galderma has Heritage of Successful Drugs in Acne and Rosacea
Slide 5: Reaching Favorable Commercialization Agreement
REACHING FAVORABLE COMMERCIALIZATION AGREEMENT Option to Regain Commercialization Rights after 5 Years at No Cost $11 million in upfront and product approval payments Mid- to high-teen percentage of royalties on net salesUp to an additional $9 million in sales milestone payments Option to regain com
Slide 6: TWYNEO Offering Comprehensive Treatment for Acne Patients
TWYNEO® OFFERING COMPREHENSIVE TREATMENT FOR ACNE PATIENTS First and only FDA Approved Fixed‑Dose Combination of Tretinoin and Benzoyl Peroxide Acne vulgaris is a multifactorial disease. Even though benzoyl peroxide and tretinoin are widely prescribed separately and have a complementary mechanism of
Slide 7: Treating Severe Acne Patient
BASELINE “Severe”; 29 inflamed lesions31 non-inflamed lesions; 1 nodule WEEK 12 “Moderate”; 9 inflamed lesions5 non-inflamed lesions; No nodules TREATING SEVERE ACNE PATIENT Subject 507-003 || 18 Years Old | Female | White | Not Hispanic or Latino* * Individual results vary
Slide 8: EPSOLAY for Inflammatory Lesions of Rosacea
Inflammatory lesions of rosacea resemble acne vulgaris, except that comedones (whiteheads and blackheads) are absent and only inflammatory lesions existEPSOLAY contains encapsulated benzoyl peroxide, using Sol‑Gel’s patented technology. Benzoyl peroxide is an effective antibacterial drug that is not
Slide 9: Treating Severe Rosacea Patient
BASELINE “Severe”; 31 inflamed lesions WEEK 2 “Clear”; No inflamed lesions “Clear”; No inflamed lesions WEEK 12 “Almost Clear”; 1 inflamed lesion WEEK 8 “Clear”; No inflamed lesions TREATING SEVERE ROSACEA PATIENT Subject 116-009 || 41 Years Old | Female | White | Not Hispanic or Latino* WEEK 4 * In
Slide 10: Focusing on Innovative Pipeline While Securing Non-Dilutive Funding
FOCUSING ON INNOVATIVE PIPELINE WHILE SECURING NON-DILUTIVE FUNDING Sale of Generic Assets to Padagis $21 million in quarterly installments over 24 monthsProceed with 50/50 gross profit-sharing collaboration on 2 programs encompassing 4 high-value generic drug candidates Allows for focus on innovati
Slide 11: Pursuing Leadership in Dermatology
pre-clinical phase II phase III filed research phase I pre-clinical phase II phase III filed research phase I FDA approval07/26/21 EPSOLAY®Benzoyl Peroxide Cream, 5%Inflammatory Lesions of Rosacea TWYNEO® Tretinoin and Benzoyl Peroxide Cream, 0.1%/3%Acne Vulgaris SGT-510Topical RoflumilastPsoriasis
Slide 12: Developing First Erlotinib Topical Drug: SGT-210
Initiate clinical development with a higher concentration of erlotinib in H2 22 DEVELOPING FIRST ERLOTINIB TOPICAL DRUG SGT-210 for Palmoplantar Keratoderma and other Skin Conditions NEXTSTEPSSGT-210 12 patent applications for erlotinib in various skin conditions (as of August 16, 2021)Potential IP
Slide 13: Developing Novel Tapinarof Cream: SGT-310
Initiate clinical development in H2 22 DEVELOPING NOVEL TAPINAROF CREAM SGT-310 for Psoriasis and other Skin Conditions NEXTSTEPSSGT-310 31 patent applications for tapinarof in various skin conditions (as of August 16, 2021)Potential IP protection until 2042 SGT-310 is intended to be an alternative
Slide 14: Developing Novel Roflumilast Topical Drug: SGT-510
SGT-510 is designed to be potentially more effective than roflumilast cream, 0.3%, for which an NDA was already submitted to the FDA DEVELOPING NOVEL ROFLUMILAST TOPICAL DRUG SGT-510 for Psoriasis and other Skin Conditions NEXTSTEPSSGT-510 A patent application was filedPotential IP protection until
Slide 15: Securing a Strong Balance Sheet
Financials September 30, 2021 Cash and Investments $45.6 million Shares Outstanding 23,119,068 ordinary shares Expected Partnership Payments EPSOLAY approval milestone payment (if approved); Quarterly payments by Padagis; Royalties from Galderma Cash Runway Based on expected payments from Galderma a
Slide 16: Building Our Future: Investor Highlights
BUILDING OUR FUTURE Investor Highlights Completed development of EPSOLAY and TWYNEO Gained FDA approval for TWYNEOEPSOLAY pre-approval inspection has been scheduled Built a strong balance sheet that currently allows for financing of operations until the end of 2023 Secured additional $21 million by
Slide 17: Sol-Gel: Advanced Topical Therapy
$ Sol- Gel ey nced Topical Therapy
Sol-Gel Technologies — Investor Presentation (January 2022) on 6ix